Helicobacter pylori: Determinant and markers of virulence

Disease Markers

Volumn 27, Issue 3-4, 2009, Pages 137-156

  Mascellino, M T ^a   Margani, M ^a   Oliva, A ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

Helicobacter pylori associated infections; Immune response and immunopathology; Multiplex PCR; Serological markers; Virulence determinants

Indexed keywords

CAGA PROTEIN; HEAT SHOCK PROTEIN 60; UREASE; VACUOLATING TOXIN; BIOLOGICAL MARKER;

BACTERIAL VIRULENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; ENDOSCOPY; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST SUSCEPTIBILITY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INNATE IMMUNITY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SCREENING; GENETICS; HUMAN; IMMUNOLOGY; PATHOGENICITY; VIRULENCE;

HELICOBACTER PYLORI;

BIOLOGICAL MARKERS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; VIRULENCE;

EID: 73349119134     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/863493     Document Type: Review

References (134)

1. R.A. Alm and T.J. Trust, Analysis of the genetic diversity of Helicobacter pylori: the tale of two genomes, J Mol Med 77 (1999), 834-846.
2. A. Amedei, A. Cappon, G. Codolo, A. Cabrelle, A. Polenghi, M. Benagiano, E. Tasca, A. Azzurri, M.M. D'Elios, G. Del Prete and M. de Bernard, The neutrophil activating protein of Helicobacter pylori promotes Th1 immune responses, J Clin Invest 116 (2006).
3. L.P. Andersen, S. Kiilerick, G. Pedersen, A.C. Thoreson, F. Jorgensen, J. Rath, N.E. Larsen, O. Borup, K. Krogefelt, J. Scheibel and S. Rune, An analysis of seven different methods to diagnose Helicobacter pylori infections, Scand J Gastroenterol 33 (1998), 24-30.
4. T. Ando, M.Wassenaar, R.M. Peek, R.A. Aras, A.I. Tschumi, L.J. van Doorn, K. Kusugami and M.J. Blaser, A Helicobacter pylori restriction endonuclease replacing gene, hrgA, is associated with gastric cancer in Asian strains, Cancer Res 62 (2002), 2385-2389.
5. T. Ando, R.A. Aras, K. Kusugami, M.S. Blaser and T.M. Wassenaar, Evolutionary history of hrg A, which replaces the restriction gene hpy IIIR in the hpy III locus of Helicobacter pylori, J Bacterial 185 (2003), 295-301.
6. T. Ando, M. Minami, K. Ishiguro, O. Maeda, O. Watanabe, T. Mizuno, T. Fujita, H. Takahashi, M. Noshiro and H. Goto, Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication, Aliment Pharmacol Ther 24 (2006), 58-64.
7. B.J. Appelmelk, I. Simoons-Smit, R. Negrini, A.P. Moran, G.O. Aspinall, J.G. Forte, T.D. Vries, H. Quan, T. Verboom, J.J. Maaskant, P. Ghiara, E.J. Kuipers, E. Bloemena, T.M. Tadema, R.R. Townsend, K. Tyagarajan, J.M. Crothers Jr., M.A. Montero, A. Savio and J. de Graaff, Potential role of molecular mimicry between Helicobacter pylori lipopolisaccharide and host Lewis blood group antigens in autoimmunity, Infect Immun 64 (1996), 2031-2040.
8. J.C. Atherton, P. Cao, R.M. Peek et al., Mosaicism in vacuolating cytotoxin alleles of Helicobacter: association of specific vacA types with cytotoxin production and peptic ulceration, J Biol Chem 270 (1995), 17771-17777.
9. J.C. Atherton, R.M. Peek, K.T. Tham, T.L. Cover and M.J. Blaser, Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori, Gastroenterology 112 (1997), 92-99.
10. J.C. Atherton, H. pylori virulence factors, British Medical Bulletin 54 (1998), 105-120.
11. S.C. Baik, K.M. Kim, S.M. Song et al., Proteomic analysis of the sarcosineinsoluble outer membrane fraction of Helicobacter pylori strain 26695. J Bacteriol 186 (2004), 949-955.
12. K.B. Bamford, X. Fan, S.E. Crowe et al., Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype, Gastroenterology 114 (1998), 482-492.
13. M.P. Bergman, A. Engering, H.H. Smits, S.J. van Vliet, A.A. van Bodegraven, H.P. Wirth, M.L. Kapsenberg, C.M. Vandenbroucke-Grauls, Y. van Kooyk and B.J. Appelmelk, Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN, J Exp Med 200 (2004), 979-990.
14. J.E. Beswick, I.V. Pinchuck, K. Minch, G. Suarez, J.C. Sierra, Y.Yamaoka andV.E. Reyes, The Helicobacter pylori UreasB Subnit Binds to CD74 on Gastric Epithelial Cells and Induces NF-kB Activation and Inteleukin-8 Production, Infection and Immunity (2006), 1148-1155.
15. M.J. Blaser, G.I. P̀erez-P̀erez, H. Kleanthas et al., Infection with Helicobacter pylori strains possessing cagA is associated with an increate risk of developing adenocarcinoma of the stomach, Cancer Res 55 (1995), 2111-2115.
16. K. Bodger, J.L.Wyatt and R.V. Heatley, Serologic screening before endoscopy: the value of Helicabacter pylori serology, serum recognition of the CagA and VacA proteins, and serum pepsinogen I, Scand J Gastroenterol 34 (1999), 856-863.
17. M. Boncristiano, S.R. Paccani, S. Barone, C. Ulivieri, L. Patrussi, D. Ilver, A. Amedei, M.M D'Elios, J.L. Telford and C.T. Baldari, The Helicobacter pylori Vacuolating Toxin Inhibits T Cell Activation by Two Independent Mechanisms, J Exp Med 198 (2003), 1887-1897.
18. G.N. Borlace, R.S. Butler and D.A. Brooks, Monocyte and Macrophage Killing of Helicobacter pylori: Relationship to Bacterial Virulence Factors, Helicobacter ISSN 13 (2008), 380-387.
19. S. Bortolin, M. Black, H. Mod̀i, I. Boszko, D. Kobler, D. Fieldhouse, E. Lopes, J.M. Lacroix, R. Grimlood, P. Wells, R. Janeczko and R. Zastacuny, Clin Chem 11 (2004), 2028-2036.
20. K.M. Bourzac and K. Guillelmin, Helicobacter pylori-host cell interactions mediated by tipe IV secretion, Cellular Microbiol 7 (2005), 911-919.
21. J. Calam, Helicobacter pylori modulation of gastric acid, Yale Biol Med 72 (1999), 195-202.
22. S. Censini, C. Lange, Z.Y. Xiang et al., CagA pathogenicity island of Helicobacter pylori, encoder type I-specific and disease associated virulence factors, Proc Natl Acad Sci USA 93 (1996), 14648-14653.
23. Center for Disease Control. Universal precaution for prevention of transmission of human himmunodeficiency virus, hepatitis B virus and other bloodborne pathogens in healtcare settings, United States Morbid Mortal Weekly Rep 37 (1988), 377-382, 387-388.
24. R. Chen, L. Lowe, J.D. Wilson, E. Crowther , K. Tzeggai, J.E. Bishop and R.Varro, Clin Chem 9 (1999), 1693-1694.
25. S. Copeland, J. Siddiqui and D. Remick, Direct comparison of traditional ELISAs and membrane protein arrays for detection and quantification of human cytokines, J Immunol Methods 284 (2004), 99-106.
26. E. Corrado and S. Novo, Role of inflammation and infection in vascular disease, Acta Chir Belg 105 (2005), 567-579.
27. P. Correa, Human gastric carcinogenesis:a multistep and multifactorial process-first American Cancer Society Award Lecture on cancer epidemiology and prevention, Cancer Res 52 (1992), 6735-6740.
28. T.L. Cover, S.G. Vaughn, P. Cao et al., Potentation of Helicobacter pylori vacuolating toxin activity by nicotine and other weak bases, J Infect Dis 166 (1992), 1073-1078.
29. J.E. Crabtree, A. Covacci, S.M. Farmery et al., Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype, J Clin Pathol Jan 48 (1995), 41-45.
30. M.O. Dayhoff, R.M. Schwartz and B.C. Orcutt, A model of evolutionary change in proteins, in: DC: National Biomedical, M.O. Dayhoff, ed., Atlas of protein sequence and structure, Washington 1978, pp. 345-352.
31. A.Dubois, D.E. Berg, E.T. Incecik, N. Fiala, L.M. Heman-Ackah, G.I. Perez-Perez and M.J. Blaser, Transient and persistent infections of non-human primates with Helicobacter pylori: implications for human disease, Infect Immun 64 (1996), 2885-2891.
32. N.C. Du Pont, K.Wang, P.D.Wadhwa, J.F. Culhane and E.L. Nelson, J Reprod Immunol 66 (2005), 175-191.
33. M.C. Earley, R.F. Vogt, H.M. Shapiro, F.F. Mandy, K.L. Kellar, R. Bellisario, K.A. Pass, G.E. Mart, C.C. Stewart and W.H. Hannon, Cytometry 2 (1998), 239-242.
34. E.M. El-Omar, M. Carrington, W.H. Chow, K.E. McColl, J.H. Bream, H.A.Young, J. Herrera, J. Lissoluska, C.C.Yuan, N. Rothman, G. Lanyon, M. Martin, J.F. Fraumeni Jr. and C.S. Rabkin, Interleukin-1 polymorphisms associated with increased risk of gastric cancer, Nature 404 (2000), 398-402.
35. E.M. El-Omar, The importance of interleukin 1beta in Helicobacter pylori associated disease, Gut 48 (2001), 743-747.
36. E.M. El-Omar, C.S. Rabkin, M.D. Gammon, T.L. Vaughan, H.A. Risch, J.B. Schoenberg, J.L. Stanford, S.T. Mayne, J. Goedert, W.J. Blot, J.F. Fraumeni Jr. and W.H. Chow, Increased risk of Nocardia gastric cancer associated with proinflammatory cytokine gene polymorphisms, Gastroenterology 124 (2003), 1193-1201.
37. M.F. Elshal and J.P. Mc Cay, Multiplex bead array assays: Performance evaluation And comparison of sensitivity to ELISA, Science Direct 4 (2006), 317-323.
38. C. Espinola-Klein, H.J. Rupprecht, S. Blankenberg, C. Bikel, H. Kopp, G. Rippin, A.Victor, G. Hafner, W. Schumberger and J. Meyer, Impact of infectious burden on extent and long prognosis of atherosclerosis, Circulation 105 (2002), 15-21. (Pubitemid 34049136)
39. D.J. Evans, D.G. Evans, H.C. Lampert and H. Nakano, Identification of far new prokaryotic bacterioferritins from Helicobacter pylori, Anabaena variabilis, acillus subtilis and Treponema pallidum, by analysis of gene sequences, Gene 153 (1995), 123-127.
40. D.J. Evans, D.G. Evans, T. Takemura et al., Characterization of Helicobacter pylori neutrophil activating protein, Infect Immun 63 (1995), 2213-2220.
41. D.G. Evans, D.M. Queiroz, E.N. Mendes et al., Helicobacter pylori cagA status and s and m alleles of vacA in isolates from individuals with a variety of H. pylori-associated gastric diseases, J Clin Microbiol 36 (1998), 3435-3437.
42. C. Figueiredo, L.J. van Doorn, C. Nogueira et al., Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains, Scand J Gastroenterol 36 (2001), 128-135.
43. J.G. Fox, P. Beck, C.A. Dangler et al., Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter induced gastric atrophy, Nat Med May 6 (2000), 536-542.
44. T. Furuta, K. Ohashi, K. Kosuge, X.J. Zhao, M. Takashima, M. Kimura, M. Nishimoto, H. Hanat, E. Kaneko and T. Ishizaki, CYPC19 genotype status and effect of omeprazole on intragastric pH in humans, Clin Pharmacol Ther 65 (1999), 552-561.
45. T. Furuta, E.M. El-Omar, F. Xiao, N. Shirai, M. Takashima and H. Sugimura, Interleukin 1 beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duoenal ulcer recurrence in Japan, Gastroenterology 123 (2002), 92-105.
46. A. Galmiche, J. Rassow, A. Doye et al., The N-terminal 34kD fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release, EMBO J 19 (2000), 6361-6370.
47. B. Gebert, W. Fischer, E. Weiss, R. Hoffmann and R. Haas, Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation, Science 301 (2003), 1099-1102.
48. C. Genisset, C.L. Galeotti, P. Lupetti et al., A Helicobacter pylori vacuolating toxin mutant that fails to oligomerize has a dominant negative phenotype, Infect Immun 74 (2006), 1786-1794.
49. Y. Glupczynski, Microbiological and serological diagnostic tests for Helicobater pylori: an overview, British Medical Bullettin 54 (1998), 175-186. (Pubitemid 28105325)
50. A.P. Gobert, D.J. McGee, M. Akhtar, G.L. Mendz, J.C. Newton, Y. Cheng, H.L. Mobley and K.T. Wilson, Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival, Proc Nat Acad Sci USA 98 (2001), 13844-13849.
51. K.J. Goodman and P. Correa, The transmission of Helicobacter pylori: a critical review of the evidence, Int J Epidemiol 24 (1995), 875-887.
52. F.H. Guo, X.M. Yan, C.X. Fan, F. Zhao, D. Xiao, X. Zheng, M.J. Zhang, L.H. He, F.L. Meng and J.Z. Zhang, Cross reactivityof anti-H. pylori antibodies with membrane antigens of human erythrocytes, World J Gastroenterol 13 (2007), 3742-3746.
53. N. Hamajima, N. Katsuda, K. Matsuo, T. Saito, K. Hirose, M. Inoue, T.T. Zaki, K. Tajima and S. Tominaga, High anti Helicobacter pylori antibody seropositive associated with the combination of Il-8-251TT and IL-10-819Tt genotypes, Helicobacter 8 (2003), 105-110.
54. N. Hamajima, A. Shibata, N. Katsuda, K. Matsuo, H. Ito, T. Saito, K. Tajima and S. Tominaga, Subjects with TNFA-857TT and-1031TT genotypes showed the highest Helicobacter pylori seropositive rate compared with those with other genotypes, Gastric Cancer 6 (2003), 230-236.
55. S. Hellmig, J. Hampe, U.R. Folsch and S. Schreiber, Role of IL-10 promoter haplotypes in Helicobacter pylori associated gastric inflammation, Gut 54 (2005), 888.
56. A. Hildesheim, R.L. Ryan, E. Rineart, S. Nayak, D. Wallace, P.E. Castle, S. Niwa and W. Kopp, Cancer Epidemiol Biomarkers Prev 11 (2002), 1477-1484.
57. A. Hoffmeister, D. Rothenbacter, G. Bode, K. Persson, W. Marz, M.A. Nauck, H. Brenner, V. Hombach andW. Koenig, Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile, Arterioscler Thromb Vasc Biol 21 (2001), 427-432.
58. J.G. Hovey, E.L. Watson, M.L. Langford, E. Hildebrandt, S. Bathala, J.R. Bolland, D. Spadafora, G.L. Mendez and D.J. Mc Gee, Genetic microheterogenicity and phenotypic variation of Helicobacter pylori arginase in clinical isolates, BMC Microbiology 7 (2007), 26.
59. I.R. Hwang, T. Kodama, S. Kikuchi, K. Sakai, L.E. Peterson, D.Y. Graham and Y. Yamaoka, Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1 beta production in Helicobacter pylori infection, Gastroenterology 123 (2002), 1793-1803. (Pubitemid 35408303)
60. D. Ilver, A. Arnqvist, J. Ögren et al., Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging, Science 279 (1998), 373-377.
61. R. Inoue, N. Kondo, Y. Kobayashi, O. Fukutomi and T. Orii, IgG2 deficiency associated with defects in production of interferon-gamma; comparison with common variable immunodeficiency, Scand J Immunol 41 (1995), 130-134.
62. N. Kaklikkaya, K. Cubukcu, F. Aydin, T. Bakir, S. Erkul, I. Tosun, M. Topbas, Y. Yazici, C.K. Buruk and M. Erturk, Significance of cagA status and vacA subtype of Helicobacter pylori in determining gastric histopatology, Journal of Gastroenterology and Hepatology 21 (2006), 1042-1047.
63. M. Kanbay, G. Gur, M. Yucel, U. Yilmaz and S. Boyacioglu, Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci 50 (2005), 1228-1231.
64. K.L.Kellar and J.P. Douglas, J Immunol Methods 279 (2003), 277-285.
65. J.R. Kettman, T. Davies, D. Chandler, K.G. Oliver and R.J. Fucton, Cytometry 2 (1998), 234-243.
66. K. Keyes, L. Mann, K. Cox, P. Treadway, P. Iverson, Y.F. Chen and B.A. Teicher, Cancer Chemother Pharmcol 4 (2003), 321-327.
67. S.S. Khan, M.S Smith, D. Reda, A.F. Suffredini and J.P. Mc Coy Jr., Cytometry B Clin Cytom 61 B 1 (2004), 35-39.
68. T. Kita, Y. Tanigaluara, N. Aoyama, T. Hohda, Y. Saijoi, F. Komada, T. Sakaeda, K. Okumura, T. Sakai and M. Kasuga, CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability, Phar Res 18 (2001), 615-621.
69. T.U. Kosunen, J. Hook, H.I. Rautelin and G. Myllyla, Age dependent increase of Campylobacter pylori antibodies in blood donors, Scan J Gastroenterol 24 (1989), 110-114.
70. S. Koyama, Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: human glandular stomach as a site of immune privilege, Dig Dis Sci 45 (2000), 77.
71. T. Kudo, H. Lu, J.Y. Wu et al., Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori, Infect Immun 73 (2005), 7602-7612. (Pubitemid 41587667)
72. J.G. Kusters, A.H.M. Van Vliet and E.J. Kuipers, Pathogenesis of Helicobacter pylori Infection, Clin Microboe Rev 19(3) (2006), 449-490.
73. A. Laurila, A. Bloigu, S. Nayha, J. Hassi, M. Leinonem, P. Saikku, Association of Helicobacter pylori infection with elevated serum lipids, Atherosclerosis 142 (1999), 207-210.
74. C. Lenzi, A. Palazzuoli, N. Giordano, G. Alegente, C. Gonnelli, M.S. Campagna, A. Santucci, M. Sozzi, P. Papakostas, F. Rollo, R. Nuti and N. Figura. H. pylori infections and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease, World J Gastroenterol 48 (2006), 7815-7820.
75. D.P. Letley and J.C. Atherton, Natural diversity in the N terminus of the mature vacuolating cytotoxin of Helicobacter pylori determines cytotoxin activity, J Bacteriol 182 (2000), 3278-3280.
76. H. Li, C. Stoicov, X. Cai et al., Helicobacter and gastric cancer disease mechanisms: host response and disease susceptibility, Curr Gastroenterol Rep Dec 5 (2003), 459-467.
77. Y. Li, A. Wandinger-Ness, J.R. Goldenring and T.L. Cover, Clustering and redistribution of late endocytic compartments in response to Helicobacter pylori vacuolating toxin, Mol Biol Cell 15 (2004), 1946-1959.
78. A.G. Lim , R.M. Martin, M. Monteleone, A.C. Walker and S.R. Gould, Helicobacter pylori serology and the managment of young dydpeptics: a UK survey of gastroenterologists and general practitioners with an interest in gastroenterology, Aliment Pharmacol Ther 11 (1997), 299-303.
79. S. Lindquist and E.A. Craig, The Heat shock proteins, Annu Rev Genet 22 (1988), 631-677.
80. A. Locatelli, W.R. Catapani, C.R. Gomes Junior, C. Battistin, Paula Silva and J. Waisberg, Detection of Anti-Helicobacter pylori antibodies in serum and duodenal fluid in peptic gastroduodenal disease, World J Gastroentreol 10 (2004), 2997-3000.
81. R.P.H. Logan and D.E. Berg, Genetic diversity of Helicovbacter pylori, Lancet 348 (1996), 1462-1463.
82. A. Lozniewski, F. Muhale, R. Hatier et al., Human embryonic gastricxenografts in nude mice: a new model of Helicobacter pylori infection, Infect Immun 67 (1999), 1798-1805.
83. W. Lu, K. Pan, L. Zhang, D. Lin, X. Miao and W. You, Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor alpha and risk of gastric cancer in a Chinese population, Carinogenesis 26 (2005), 631-636.
84. M. Marchetti, B. Aric̀o, D. Burroni et al., Development of a mouse model of Helicobacter pylori infection that mimics human disease, Science 267 (1995), 1655-1658.
85. J.C. Machado, C. Figureido, P. Canedo, P. Pharoah, R. Carvalho, S. Nabais, C. Castroalves, M.L. Campos, L.J. van Doorn, C. Caldas, R. Seruca, F. Carneiro and M. Sobrinho-Simoes, Apro-inflammatory genetic profile increases the risk of chronic atrophic gastritis and gastric carcinoma, Gastroenterology 125 (2003), 364-371.
86. M.T. Mascellino, M.R. Ciardi, A. Oliva, F. Cecinato and L. Borgese, Chlamydia trachomatis detection in a population of asymptomatic and symptomatic women: correlation with the presence of serological markers for this infection, New Microbiologia 31 (2008), 249-256.
87. M.S. McClain, P. Cao, H. Iwamoto et al., The 12-aminoacid segment present in type s2 but not type s1 Helicobacter pylori VacA proteins, abolishes cytotoxin activity and alters membrane channel formation, J Bacteriol 183 (2001), 6499-6508.
88. K. Mc Coll, Should non-invasive Helicobacter pylori testing replace endoscopy in investigation of dydpepsia? Helicobacter 5 (2000), 11-31.
89. C.A. Mc Nulty, P. Nair, B.E. Watson, J.S. Uff and R.M. Valori, Acomparison of six commercial kits for Helicobacter pylori detection, Commun Dis Public Healt 1 (1999), 59-63.
90. H.L Mobley., L.T. Hu and P.A. Foxal, Helicobacter pylori urease: properties and role in pathogenesis, Scand J Gastroenterol Suppl 187 (1991), 39-46.
91. C. Montecucco and M. de Bernard, Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophils-activating protein (HP-NAP) virulence factors of Helicobacter pylori, Microbes Infect 5 (2003), 715-721.
92. M.A. Monteiro, K.H. Chan, D.A. Rasko, T.E. Taylor, P.Y. Zheng, B.J. Appelmelk, H.P.Wirth, M. Yang, M.J. Blaser, S.O. Hynes, A.P. Moran and M.B. Perry, Simultaneous expressionof type 1 and type 2 Lewis blood group antigens by Helicobacter pylori lipopolisaccharides. Molecular mimicry between H. pylori lipopolisaccarides and human gastric epithelial cell surface glycoforms, J Biol Chem 273 (1998), 11533-11543.
93. H.M. Nabwera and R.P. Logan, Epidemiology of Helicobacter pylori: transmission, translocation and extragastric reservois, J Phisiol Pharmacol 50 (1999), 711-722.
94. S. Nandakumar, C.W.T. Miller and U. Kumaraguru, T regulatory cells: an overview and intervention techniques to modulate allergy outcome, Clinical and Molecular Allergy 7 (2009), 5.
95. A.M.Y. Nomura, G.I. Ṕerez-Ṕerez, J. Lee, G. Stemmermann and M.J. Blaser, Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease, Am J Epidemiol 155 (2002), 1054-1059.
96. Y.N. Nozawa, K. Nishihara, R.M. Peak, M. Nakano, T. Uji, H. Ajoka, N. Matsuura and H. Miyake, Identification of a signaling cascade for Interleukin-8 production by Helicobacter pylori in human gastric epithelial cells, Biochem Pharmacol 64, 21-30.
97. K. Ogura, S. Maeda, M. Nakao et al., Virulence factors of Helicobacter pylori responsible gastric diseases in Mongolian gerbil, J Exp Med 192 (2000), 1601-1609.
98. M. Oleastro, L. Monteiro, P. Lehours, F. Ḿegraud and A Menard, Identification of markers for Helicobacter pylori strains isolated from children with peptic ulcer disease by suppressive subtractive hybridization, Infect Immun 74 (2006), 4064-4074.
99. M. Oleastro, R. Cordeiro, J. Ferrand, B. Nunes, P. Lehours, I. Carvalho-Oliveira, A. I. Mendes, D. Penque, L. Monteiro, F. Ḿegraud and A.Ḿenard, Evaluation of Clinical Significance of homB, a Novel Candidat Marker of Helicobacter pylori Strain Associated with Peptic Ulcer Disease, J Infect Dis 198 (2008), 1379-1387.
100. S. Pang, J. Smith, D. Onley, J. Reeke, M.Walker and C. Foy, J Immunol Methods 302 (2005), 1-12.
101. J. Parsonnet, G.D. Friedman, N. Orentreich and H.Vogelman, Risk factor for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 40 (1997), 297-301. (Pubitemid 27145639)
102. R.M. Peek Jr., G.G. Miller, K.T. Tham et al., Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains, Lab Invest Dec 73 (1995), 760-770.
103. A. Polenghi, F. Bossi, F. Fischetti, P. Durigutto, A. Cabrelle, N. Tamassia, M. A. Cassatella, C. Montegucco, F. Tedesco and M. De Bernard. The Neutrophil-Activating Protein of Helicobacter pylori Crosses Endotelia to Promote Neutrophic Adhesion in vivo, J Immunoe 178 (2007), 1312-1320.
104. U. Prabhakar, E. Eirikis and H.M. Davis, J Immunol Methods 260 (2002), 207-218.
105. D.M. Queiroz, J.B. Guerra, G.A. Rocha, A.M. Rocha, A. Santos, A.G. De Oliveira, M.M. Cabral, A.M. Nogueira and C.A. De Oliveira, Il-1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis, Gastroenterology 127 (2004), 73-79.
106. R. Rad, C. Prinz, B. Neum, M. Neuhoter, M. Zeitner, P. Voland, I. Becker,W. Schepp and M. Gerhard, Synergistic effect of Helicobacter pylori virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa, J Infect 188 (2003), 272-281.
107. R. Rad, A. Dossumbekova, B. Neu, R. Lang, S. Bauer, D. Saur, M. Gerhard and C. Prinz, Cytokine gene polymorphisms influence mucosal cytokine expression, gastrin inflammation, and host specific colonization during Helicobacter pylori infection, Gut 53 (2004), 1082-1089.
108. C.A. Ray, R.R. Browsher,W.C. Smith, V. Devanarayan, M.B. Willey, J.T. Brandt and R.A. Dean, J Pharm Biomed Analysis 36 (2005), 1037-1044.
109. Z. Ren, T. Borody, G. Pang, L. Chen Li, M. Dunkley and R. Clancy, Selective reduction of Anti-Helicobacter pylori IgG Subclass Antibody in Gastric Carcinoma, Journal of Gastroenterology and Hepatology 20 (2005), 1338-1345.
110. J.L. Rhead, P.D. Letley, M. Mohammad, N. Hussein, M.A. Mohagheghi, M.E. Hosseini and J.C. Atherton, A new Helicobacter pylori Vacuolating Cytotoxin Determinant, the Intermediate Region, Is Associated With Gastric Cancer, Gastroenterology 133 (2007), 926-936.
111. K. Robinson, R.H. Argent and J.C. Atherton, The inflammatory and immune response to Helicobacter pylori infection, Best Practice & Research Clinical Gastroenterology 21 (2007), 237-259.
112. J. Rudi, C.Kolb, M. Maiwald et al., Diversity of Helicobacter pylori vacA and cagA genes and relationship to vacA and CagA protein expression, cytotoxin production, and associated diseases, J Clin Microbiol 36 (1998), 944-948.
113. W. de Sager, H.T.E. Velthuis, J. Prakren, W. Kuis, G.T. Rijkers, Clin Diagn Lab Immunol 1 (2003), 133-139.
114. N. Salles and F.Megraud, Current management of Helicobacter pylori infections in the elderly, Expert Rev Anti Infect Ther 5 (2007), 845-856.
115. X. Sewald, B. Gebert-Vogl, S. Prassl, I. Barwig, E.Weiss, M. Fabbri, R. Osicka M. Schiemann, D.H. Busch, M. Semmrich, B.H.P. Sebo and R. Haas, Integrin Subunit CD18 Is the TLymphocyte Receptor for the Helicobacter pylorVaculating Cytotoxin, Cell Host and Microbe 3 (2008), 20-29.
116. S. Strobel, S. Bereswill, P. Balig, P. Allgaier, H.G. Sonntag and M. Kist, Identification and analysis of a new vacA genotype variant of Helicobacter pylori in different patient group in Germany, J Clin Microbiol 36 (1998), 1285-1289.
117. B. Su, P.M. Hellström, C. Rubio, J. Celik, M. Granström and S. Normark, Type I Helicobacter pylori shows Lewisindependent adherence to gastric cells requiring de novo protein synthesis in both host and bacteria, J Infect Dis 178 (1998), 1379-1390.
118. S. Suerbaum and P. Michetti, Helicobacter pylori infection, New England J of Med 347 (2002), 1175-1186.
119. T. Suzuki, E. Grand, C. Bowman, J.L. Merchant, A. Todisco, L.Wang and J. Del Valle, TNF-alpha and interleukin 1 activate gastrin gene expression via MAPK-and-PCK-dependent mechanisms, Am J Physiol Gastrointest Liver Physiol 281 (2001), 1405-1412.
120. W. Tell, J.R. Lambert and B. Dwyer, Cytotoxin production by Helicobacter pylori from patients with upper gastrointestinal diseases, I Clin Microbiol 33 (1995), 1203-1205.
121. S.K. Tiwari, A.A. Khan, K.S. Ahmed, S.M. Al̀i, I. Ahmed, A. Habbeb, F. Kauser, M.A. Hussain, N. Ahmed and C.M. Habibullah, Polimerase chain reaction based analysis of the cytotoxin associated gene pathogenicity island of Helicobacter pylori from saliva: An approach for rapid molecular genotyping in relation to disease status, Journal of Gastroenterology and Hepatology (2004).
122. S.K. Tiwari, A.A. Khan, K.S. Ahmed, I. Ahmed, F. Kauser, M.A. Hussain, S.M. Al̀i, Alv̀i, A. Habeeb, Z. Abid, N. Ahmed and C.H. Habibullah, Rapid diagnosis of Helicobacter pylori infection in dyspeptic patients using salivary secretion: a non-invasive approach, Singapore Med J 5 (2005), 224-228.
123. S.K. Tiwari, A.A. Khan, G. Manoj, S. Ahmed, Z. Abid, A. Habeeb and C.M. Habibullah, A simple multiplex PCR assay for diagnosing virulent Helicobacter pylori infection in human gastric biopsy specimens from subjects with gastric carcinoma and other gasto-duodenal diseases, J Appe Microboe ISSN 103 (2007), 2353-2360.
124. N.P. Tobin, G.T. Henehan, R.P. Murphy, J.C. Atherton, A.F. Guinan, S.W. Kerrigan, D. Cox, P.A. Cahill and P.M. Cummins, Helicobacter pylori-induced inhibition of vascular endothelial cell functions: a role for VacA-dependent nitric oxide reduction, Am J Physiol 295 (2008), H1403-H1413.
125. H. Tulinius, H.M. Ogmundsdottir, K.G. Kristinsson et al., Helicobacter pylori antibodies and gastric cancer in Iceland: the decline in IgG antibody level is a risk factor, APMIS 109 (2001), 835-841.
126. L.J. van Doorn, C. Figueiredo, R. Sanna et al., Expanding allelic diversity of Helicobacter pylori vacA, J Clin Microbiol 36 (1998), 2597-2600.
127. J. Viala, C. Chaput, I.G. Boneca, A. Cardona, S.E. Girardin, A.P. Moran, R. Athman, S. Memet, M.R. Huerre, A.J. Coyle, P.S. DiStefano, P.J. Sansonetti, A. Labigne, J. Bertin, D.J. Philpott and R.L. Ferrero, Helicobacter pylori responds to peptidoglycan delivered by the cag pathogenicity island, Nat Immunol 5 (2004), 1166-1174.
128. G.Wang, P. Alamuri and R.J. Maier, The diverse antioxidant systems of Helicobacter pylori. Mol Microbiol 61 (2006), 847-860.
129. J.Wang, G.E. Brooks, B.K. Bamford, T.L. Denning, J. Pappo and P.B. Ernst, Negative Selection of T Cells by Helicobacter pylori as a Model for Bacterial Strain Selection by Immune Evasion, J Immunoe 167 (2001), 926-934.
130. G.Wick, M. Knoflach, B. Henderson and D. Bernhard, Heat shock proteins and stress in atherosclerosis, Autoimm Rev 3 (2004), 30-31.
131. Z. Xiang, S. Censini, P.F. Bayeli, J.L. Telford, N. Figura, R Rappudi and A. Conacci, Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin, Infect Immun (1995).
132. Q. Xu and G. Wick, The role of heat shock proteins n prediction and pathophysiology of the arterial wall, Mol Med Today 2 (1996), 372-379.
133. Y. Yamaoka, O. Ojo, S. Fujimoto et al., Helicobacter pylori outer membrane proteins and gastroduodenal disease, Gut 55 (2006), 775-781.
134. Y. Yamaoka, Roles of Helicobacter pylori BabA in gastroduodenal pathogenesis, World J Gastroenterol 14 (2008), 4265-4272.